The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate Pim kinase activity and/or FMS-like tyrosine kinase (Flt) activity. The invention also relates in part to methods for using such molecules.
[EN] PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS<br/>[FR] DÉRIVÉS DE PIPÉRIDINE ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES MÉTABOLIQUES
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2012001107A1
公开(公告)日:2012-01-05
The invention relates to new piperidine derivatives of the formula (I) to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
Substituted pyrindinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
申请人:Jones M. Robert
公开号:US20070078150A1
公开(公告)日:2007-04-05
The present invention relates to certain substituted pyridinyl and pyrimidinyl derivatives of Fomula (Ia) that are modulators of metabolism.
Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.
Use of adenosine A2a receptor antagonists for the treatment of extrapyramidal syndrome and other movement disorders
申请人:Schering Corporation
公开号:EP2269596A2
公开(公告)日:2011-01-05
There is disclosed a method for the treatment or prevention of Extra Pyramidal syndrome (EPS), dystonia, restless leg syndrome (RLS) or periodic leg movement in sleep (PLMS) comprising the administration of an adenosine A2a receptor antagonist, alone or in combination with other agents useful for treating EPS, dystonia, RLS or PLMS.
Use of adenosine A2a receptor antagonists for the treatment of restless leg syndrome and other movement disorders
申请人:Schering Corporation
公开号:EP2295047A2
公开(公告)日:2011-03-16
There is disclosed a method for the treatment or prevention of restless leg syndrome (RLS) or periodic leg movement in sleep (PLMS) comprising the administration of an adenosine A2a receptor antagonist, alone or in combination with other agents useful for treating RLS or PLMS.